logo-shape-trans

Mechanistic Biology First

Every thesis begins with primary literature review. We understand the drug's mechanism of action before we build a financial model.

Clinical Trial Rigor

Endpoint design, patient selection, interim analysis structure, and readout probability — evaluated with the scrutiny of a regulatory professional.

Competitive Landscape Analysis

Each asset is situated within its competitive pipeline, standard of care, and regulatory precedent to form a complete picture of commercial potential.

Probability-Weighted Valuation

We assign fair value under scientific and regulatory uncertainty using EV/Peak Sales and risk-adjusted NPV frameworks refined by sector-specific priors.
red-shape

Built From the Molecule Up

Members are trained to build investment theses from first principles — understanding the drug's mechanism before evaluating its commercial potential. Our research process integrates mechanistic biology, clinical trial design, regulatory science, and probability-weighted valuation into a single analytical framework.

Members present live corporate presentations, defend theses before the Investment Committee, and develop real investment judgment on public securities.

Public Equities
5 Therapeutic Areas
Investment Committee
Image
Sector Teams

Five Therapeutic Areas of Coverage.

Student sector teams cover five therapeutic areas. Members produce original investment theses and pitch to a formal Investment Committee using primary data, clinical trial analysis, and valuation frameworks.
icon-oncology
Oncology
Investment Themes
  • IO combination strategies
  • Targeted therapies & biomarkers
  • ADC mechanism & linker science
  • Cell therapy (CAR-T, NK cells)
  • Tumor microenvironment
icon-Central-Nervous-System
Central Nervous System
Investment Themes
  • Neurodegeneration (AD, PD, ALS)
  • Psychiatric disorders & novel MOAs
  • Antisense oligonucleotides
  • Blood-brain barrier delivery
  • Biomarker-driven patient selection
icon-Rare-Disease
Rare Disease
Investment Themes
  • Orphan drug pricing dynamics
  • Lysosomal storage disorders
  • Enzyme replacement therapy
  • Breakthrough designation pathways
  • Natural history studies & endpoints
icon-Genetic-Medicine
Genetic Medicine
Investment Themes
  • AAV gene therapy tropism & dosing
  • CRISPR/base editing in vivo
  • mRNA therapeutics & lipid NPs
  • Durability of effect data
  • Manufacturing & COGS trajectory
icon-Immunology-&-Inflammation
Immunology & Inflammation
Investment Themes
  • IL pathway inhibitors
  • Autoimmune disease mechanisms
  • T-cell biology & exhaustion
  • Complement cascade targets
  • Bispecific antibody organization
Deep Dive: All Sectors
Investment Process

Our Research Framework

Members are trained to build theses from the molecule up. Our research process integrates four core disciplines into a single coherent analytical framework.
Investment Committee
"Members present live corporate presentations and defend theses — developing real investment judgment on public securities."

Coverage

5

Arm Type

Public Equities

Oversight

IC + Board

Format

Live Pitch
DCF Modeling
RNPV
Peak Sales
Endpoint Analysis
Regulatory Strategy
Pipeline Diligence
KOL Networks
Catalyst Mapping
Primary Literature
Competitive Intel
01.

Mechanistic Biology

Understanding the drug's mechanism before evaluating commercial potential. What is the target? What is the MOA? What is the preclinical evidence? What does failure look like?

MOA Analysis
Target Biology
Preclinical Data
02.

Clinical Trial Structure

Interpreting endpoint design (OS, PFS, ORR, HR), patient selection criteria, interim analysis construction, and estimating readout probability under Bayesian priors.

OS / PFS / ORR
Hazard Ratio
Patient Selection
03.

Regulatory & Competitive Landscape

Situating assets within the standard of care, competitive pipeline dynamics, FDA precedent, and label expectations that will govern commercial success.

Standard of Care
Pipeline Dynamics
Label Analysis
04.

Probability-Weighted Valuation

Assigning fair value under scientific and regulatory uncertainty using EV/Peak Sales and risk-adjusted NPV frameworks. Modeling scenarios across success, partial success, and failure.

rNPV
EV / Peak Sales
Scenario Analysis
Governance Structure

How Decisions Get Made

Sector Teams

Five independent teams, each dedicated to a therapeutic area. Sector leads manage research calendars, assign coverage, and coordinate thesis development across members.

Investment Committee

Theses are presented in live sessions before the Investment Committee. Members defend their scientific and financial analysis under structured challenge from senior members and advisors.